Lentiviral vectors have emerged as promising tools for both gene therapy and immunotherapy purposes. They exhibit several advantages over other viral systems in that they are less immunogenic and are capable of transducing a wide range of different cell types, including dendritic cells (DC). DC transduced ex vivo with a whole range of different (tumor) antigens were capable of inducing strong antigen-specific T-cell responses, both in vitro and in vivo. Recently, the administration of lentiviral vectors in vivo has gained substantial interest as an alternative method for antigenspecific immunization. This method offers a number of advantages over DC vaccines as the same lentivirus can in principle be used for all patients resulting in a significantly reduced cost and requirement for considerably less expertise for the generation and administration of lentiviral vaccines. By selectively targeting lentiviral vectors to, or restricting transgene expression in certain cell types, selectivity, safety and efficacy can be further improved. This review will focus on the use of direct administration of lentiviral vectors encoding tumor-associated antigens (TAA) for the induction of tumor-specific immune responses in vivo, with a special focus on problems related to the generation of large amounts of highly purified virus and specific targeting of antigenpresenting cells (APC).
Introduction
The concept of a sentinel role for the immune system is longstanding and was formulated by Ehrlich in his 'immune surveillance hypothesis'. 1 Instrumental to this idea is the capacity of the immune system to distinguish 'self' from 'nonself' and to eliminate the latter without damaging the former. Although this concept was originally devised for explaining immune responses against foreign invaders, it was later refined by Burnet and Thomas, 2 who applied it to antitumor immune responses in their so called 'tumor surveillance hypothesis'. Herein they propose a model where tumor cells are recognized as foreign by the immune system and subsequently specifically eliminated without damaging their healthy counterparts, much in the same way as for virus infected cells, thus avoiding autoimmunity. The identification of antigens that are specifically expressed by the tumor but not by normal tissues offered a rationale for this hypothesis. 3 These so-called tumorassociated antigens (TAA) can be divided in several groups according to their expression pattern. As melanoma constitutes the most immunogenic cancer, most of the TAA known to date were identified from melanoma tumors. Each of these antigens can give rise to a number of epitopes that will be presented by the tumor in major histocompatibility complex (MHC) class I or class II molecules and can be recognized by cytotoxic CD8 + T cells or helper CD4 + T cells, respectively, that were productively primed in the secondary lymphoid organs. 4 Extensive research into these TAA and immune responses directed against them has instigated attempts for the manipulation of the antitumor immune response by actively trying to stimulate immunity against these TAA and consequently against the tumor itself. Thus, encouraged by the immense success of prophylactic vaccines, during the last two decades several approaches of therapeutic vaccinations have been developed as an alternative treatment for cancer.
As dendritic cells (DC) are considered to be the most potent antigen-presenting cells (APC) of the immune system, one of the most well-studied vaccination approaches is the use of ex vivo-generated DC loaded with TAA in one form or another to boost/induce antitumor immune responses in cancer patients. Several approaches have been studied for loading DC with antigen, the description of which is outside the scope of this review. Broadly speaking, these can be divided in viral and nonviral methods.
Although cancer cells can potentially be distinguished from normal cells through a whole arsenal of antigens with highly restricted expression, these are still considered as self-antigens by the immune system. Thus, several tolerogenic mechanisms as well as different modes of active inhibition will impede a productive antitumor immune response. A manifestation of this phenomenon is the presence of high numbers of cytotoxic T lymphocytes (CTL) in the tumor and the periphery without measurable tumor regression. 5 Taken together, for any therapeutic vaccination strategy to be successful, it is crucial not only to induce a specific immune response against the tumor but also to overcome intrinsic tolerogenic and suppressive mechanisms.
Recently several mechanisms have been described that contribute to this lack of functional antitumor reactivity. One of the paradigms of immunology is that a productive T-cell immune response requires specific recognition of an MHC-peptide complex by the T-cell receptor (signal 1) along with adequate signaling through costimulatory molecules (signal 2). Recently, more and more data indicate that to establish strong antitumor responses, an inflammatory environment (signal 3) is required alongside functional recognition of T cells by APC. This can be achieved by strong activation of the innate arm of the immune system, in particular through toll-like receptors (TLR). Yang et al. 6 recently showed that in order to break tolerance of tumor-specific CTL, persistent TLR ligation should be provided alongside antigen-loaded mature DC. Lang et al. 7 showed that even in a transgenic mouse model where the antigen is highly expressed in the target organ (in this case the pancreas) adoptively transferred CTL were not able to lyze actually the target cells. Only concomitant TLR ligand administration induced frank diabetes.
Besides, a lack of sufficient stimulation to break tolerance, several inhibitory mechanisms, have been identified that are responsible for active quenching of the antitumor immune response. Many of these mechanisms are based on a paracrine secretion of cytokines either by the tumor or by other cells, including members of the interleukin (IL)-10 family and transforming growth factor-b. However, a new subtype of CD4 + T cells has recently emerged, which shows a contactdependent inhibitory capacity toward effector T cells. 8 In mouse studies, we and others have shown that depletion of CD4 + CD25
+ regulatory T cells (Treg) greatly enhances the antitumor response. 9, 10 Furthermore, in tumor biopsies from ovarian cancer patients, significant numbers of Treg were found which were associated with a high death hazard and reduced survival. 11 Therefore, specific removal of Treg inhibition is important to boost the antitumor response of cytotoxic CD8 + T cells. It has recently emerged that signaling through certain combinations of TLR on DC not only provides a synergy with respect to the production of cytokines such as IL-12, 12, 13 but also offers protection from Treg inhibition. 14 In light of these data, it is becoming evident that it will not be enough to merely generate mature DC efficiently presenting TAA-derived epitopes, but that additional signals need to be provided to overcome inherent mechanisms of tolerance. Although lentiviral vectors are devoid of virulence factors, they might still be a source for activation signals for the innate immune system. Together with providing sufficient amounts of antigen for T-cell priming to DC, lentiviral vectors might also contribute certain inflammatory signals (e.g., through their viral RNA). Thus, the capacity of lentiviral vectors to induce long-term transgene expression as their chief advantage might be eclipsed by their ability to offer significant amounts of 'signal 3'.
In this review, we will first describe lentiviral vectors for the transduction of DC in vitro. Ultimately, we will describe the potential use of lentiviral vectors as a vehicle for direct therapeutic vaccination.
Lentivirus-based vectors
The development of retrovirus-and lentivirus-based vectors
The use of gene delivery vectors based on retroviruses was introduced in the early 1980s by Mann et al. 15 The family of the retroviridae consists of single-stranded RNA (ssRNA) viruses, which are spherical, measure about 80-120 nm in diameter, have a mass of B2.5 Â 10 5 kDa and represent a density of 1.16 g/ml in sucrose density gradients. 16 These ssRNA viruses replicate through a double-stranded DNA intermediate, integrating their cargo into the host genome where they express viral RNA during the lifetime of the cell. The retroviridae are generally divided in two categoriessimple and complex -based on their genome organization. The most commonly used oncogenic retroviral vectors are based on Moloney Murine Leukaemia Virus (MLV) and have a simple genome. From this genome, the polyproteins, gag, pol and env are required in trans for viral replication and packaging. Required in cis are the 5 0 and 3 0 long-terminal repeat (LTR), the integration sequences as well as the packaging site c, the transport RNA-binding site and finally additional sequences involved in reverse transcription. To generate replication-deficient retroviral vectors, the gag, pol and env genes are replaced with an expression cassette.
The major advantage of retroviral vectors in view of inducing antitumor responses is their lack of immunogenicity due to the removal of most genes encoding viral proteins, thus enabling repeated use of these vectors for immunization. However, there are some limitations associated with oncogenic retroviral vectors. The most important are: (1) the instability of the viral particle, 17 (2) the low viral titers 18 and (3) the inability to transduce nondividing cells. 19 To overcome these shortcomings, lentivirus-based vectors were developed. 20 Lentiviruses constitute a subclass of retroviruses of which mainly simian immunodeficiency virus (SIV) and human immunodeficiency virus (HIV) have been extensively studied. They display the same basic genomic organization as oncogenic retroviruses, 21 but are more complex due to the presence of accessory genes -vif, vpr, vpu, nef, tat and rev -some of which play crucial roles in virus replication (Figure 1 ). 22 Unlike retroviruses, lentiviruses are capable of transducing quiescent cells. 23 For HIV, this process appears to be facilitated by the following viral proteins: (1) the integrase protein, 24, 25 (2) the matrix protein from gag, 26 (3) the accessory protein vpr 27 and (4) the central polypurine tract (cPPT). 28 As a result of their capacity to transduce nondividing cells -although for some cell types, progression through the cell cycle from G0 to G1b is necessary for efficient, complete reverse transcription of the viral genome 29 -lentiviral vector development has received much interest.
In analogy with the design of oncogenic retroviral vectors, the design of lentiviral vectors is based on the separation of cis-and trans-acting sequences. Generally,
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K Breckpot et al lentiviral particles are generated through transient transfection of three plasmids in the human embryonal kidney (HEK) 293T producer cell line. 30 The plasmids in question are: (1) a packaging plasmid, (2) a transfer plasmid and (3) an envelope-encoding plasmid. The lentiviral particles are divided into 'generations' according to which packaging plasmid was used for virus production. The first-generation packaging construct provided the entire gag and pol sequences in trans to enable packaging of the transfer construct and contains the viral regulatory genes tat and rev along with the accessory genes vif, vpr, vpu and nef. Identification of the HIV genes that are necessary for virulence, but disposable for transfer of the genetic cargo, allowed the engineering of multiple-attenuated packaging systems. 22, 31 In these second-generation packaging systems, up to four accessory genes (vif, vpr, vpu and nef) were removed without negative effects on yield or infection efficiency in most cell types. These minimal packaging systems gained in safety, as any replication-competent lentivirus (RCL) that was still generated would be devoid of all virulence factors. Safety was further improved by engineering split-genome packaging systems (third generation), where the rev gene is expressed from a separate plasmid. Finally, tat could be removed by placing a strong constitutional promoter in the 5 0 LTR of the transfer vector. 32 The transfer plasmid consists of an expression cassette as well as the HIV cis-acting factors necessary for packaging, reverse transcription and integration. Engineering of self-inactivating (SIN) transfer vectors by deleting the U3 region of the 3 0 LTR 33,34 not only further minimized the risk of emergence of RCL, but also decreased problems related to promoter interference. 35 Nuclear import of the transfer construct was improved by including the cPPT and its central termination sequence, together forming a triple helix (TRIP). This structure mediates the transport of the preintegration complex through the nuclear pores. TRIP/cPPT-containing transfer vectors yield higher virus titers and provide enhanced transgene expression in the target cells. 28, 36 Addition of post-transcriptionally active elements, such as the woodchuck hepatitis B post-transcriptional regulatory element (WPRE), represents another strategy to improve the lentiviral vector design. WPRE may improve gene expression by modification of polyadenylation, RNA export or translation (Figure 2 ). 37 The third plasmid required for lentivirus production, provides a heterologous envelope, in most cases the glycoprotein of vesicular stomatitis virus (VSV.G), which allows the formation of mixed particles or pseudotypes, displaying the tropism of the virus from which the envelope is derived. 38 This topic is discussed in more detail in the following section. Lentiviral vectors in cancer immunotherapy K Breckpot et al lentiviral vectors is VSV.G. Lentiviral vectors pseudotyped with VSV.G offer significant advantages in that VSV.G appears to interact with a ubiquitous cellular receptor on cells, endowing the vector with a broad host-cell range. 39, 40 Furthermore, VSV.G confers high vector particle stability, allowing downstream processing of the viral particles. 41 Possible shortcomings associated with the use of VSV.G are (1) its toxicity when constitutively expressed 42 and (2) its inactivation by serum complement. 43 However, the latter can be overcome by using chemically modified VSV.G pseudotypes, for example, polyethylene glycol modified particles. 43, 44 There is an ever growing list of alternative glycoproteins for pseudotyping lentiviral vectors, each with its advantages and disadvantages. This list includes the glycoproteins from rhabdoviridae, arenaviridae, flaviviridae, paramyxoviridae, baculoviridae, filoviridae and retroviridae. These glycoproteins have been successfully used for pseudotyping HIV-1 and/or SIV-derived vectors. Importantly, all of these glycoproteins preferentially interact with certain cell types, and can thus be applied to obtain cell-specific transgene expression. An overview is given in Table 1 .
Transcriptional regulation and targeting: the promotor.
For many applications, the potential to regulate or obtain cell-specific expression is appealing. Therefore, several groups have focused their research on the use of inducible or tissue-specific promoters.
Among the most widely used induction systems, the tetracycline-based approach has been adapted for transcriptional regulation of transfer vectors. [45] [46] [47] For gene-therapy applications, an inducible vector dependent on the delivery of the antibiotic (tet-on) is preferred over one based on gene silencing, which would necessitate constant antibiotics treatment in patients unless transgene expression is required, whereas in the tet-on system, antibiotics are only given when the gene needs to be turned on. With the exception of two reports, 46, 48 all the tetracycline-inducible HIV-1 vectors listed in the literature were constructed using the tet-on system. 49, 50 The authors showed that the tetracycline approach applied to HIV-1 gene transfer vectors allows inducible expression, that is dose-dependent and rapidly switched on and off.
To direct specifically transgene expression in particular cell types or organs, several groups have used tissuespecific promoters. To date, specific gene expression has been described for several cell types. Specific targeting of cells from the erythroid lineage 51 was obtained with the ankyrin-1 promoter. Endothelial cells 52 have been successfully targeted using the angiopoietin receptor Tie2. Cells from the central nervous system 53 showed a higher transgene expression on transduction with enolase promoter containing lentiviral vectors when compared to the cytomegolovirus (CMV) containing viruses both in vitro and in vivo. Use of the rhodopsin promoter in an HIV-1-based vector has not only led to photoreceptorspecific expression, but also to higher expression levels than with constitutive promoters.
54 Liver-specific expression has been achieved using the albumin promoter. 55 Moreover, Oertel et al. 56 observed that long-term expression in rat liver was achieved when the transgene was driven by the liver-specific albumin promoter but was silenced when the CMV promoter was used. In view of anticancer therapy, it is important to elaborate on the use of specific promoters to restrict transgene expression to cancer cells and cells involved in the antitumor immune response. Human hepatocarcinoma cells have been transduced with lentiviruses containing a suicide gene under the control of the a-fetoprotein promoter resulting in specific destruction of these malignant cells. 57 Furthermore, a patient-derived prostate-specific antigen (PSA) promoter inserted into a lentiviral vector has driven efficient transgenic activity in prostate cells with satisfactory efficacy and specificity both in vitro and in vivo. 58 More recently, a PSA promoterbased HIV-1 vector has been used to deliver the diphtheria toxin A gene into prostate cancer cells, resulting in tissue-specific eradication of prostate cancer cells in cell culture and in a mouse tumor model. 59 As discussed in the general introduction, APC and in particular the DC constitute an interesting cell population in view of immunotherapy. To achieve APC-specific transgene expression, Cui et al. 60 took advantage of the fact that MHC class II genes are expressed selectively in APC and highly in DC after differentiation and maturation. Using the non obese diabetic (NOD)/severe combined immunodeficient (SCID) mouse engraftment model, they demonstrated selective expression of the transgene in MHC class II positive human cells with an HIV-1 SIN vector harboring the human MHC class II-specific HLA-DRa promoter.
Downstream processing of lentiviral vectors
Production of lentiviral vectors. For small-scale experimental purposes, lentiviral vectors have been often generated through transient transfection of the producer cell line HEK 293T, with plasmids encoding for the structural proteins, enzymes, envelope and viral RNA to be packaged. However, upscaling the production in a reproducible and standardized fashion will be essential for lentiviral vectors to enter the clinic. Important parameters influencing large-scale vector production are the choice of producer cell line, media and type of vessel for cell culture. 61 The development of producer cell lines will be discussed in the following section. Concerning the cell culture vessel, advantages of reactors, such as stirred tanks, over multiple systems, such as T-flasks, cell factories and roller bottles include (1) scalability, (2) use of perfusion methods and (3) access to control units, allowing close monitoring of the culture conditions. Until now, it has been described that the best results are obtained in reactors that allow high cell density. 62, 63 Comparison of stationary versus different microcarrier cultures and the latter versus roller bottle cultures have been performed, showing that in both comparisons, the microcarrier cultures were superior for the production of high-titer vector stocks, generating titers of about 10 7 TU/ml, which are approximately a factor 2 higher than the traditional producer systems.
Producer cell lines for lentivirus production. Although numerous groups reported attempts to generate stable, well-characterized packaging cell lines, [64] [65] [66] [67] [68] [69] none of these systems are currently widely used, probably because the overall benefit compared to transient transfection remains relatively modest. The major problem with the development of such cell lines is the cytotoxicity of constitutive expression of high amounts of HIV-1 proteins, such as pol, gag, vpr, tat, rev and protease. [70] [71] [72] [73] Furthermore, the constitutive expression of the widely used envelope protein VSV.G is detrimental to mammalian cells. 41 Engineering inducible expression under the control of a drug-dependent element of both the viral proteins and VSV.G has resulted in stable packaging cell lines, resulting in acceptable vector yield, varying between 10 5 and 10 7 TU/ml. [64] [65] [66] [67] Alternatively, replacing VSV.G with glycoproteins displaying an equally broad tropism but that do not lead to producer cell death, such as baculovirus envelope, 74 gammavirus envelope 68 or alphavirus envelope, 69 has enabled the establishment of stable packaging cell lines. However, it is obvious that only virus production with stable packaging cell lines can meet the demands for clinical use when it comes to reproducibility and standardization.
Concentration and purification of lentiviral particles.
Large-scale, high-titer vector production is challenging due to the lack of simple procedures for rapidly processing large volumes of cell culture supernatant. Traditionally, physical concentration methods, including ultracentrifugation and ultrafiltration of virus-containing cell culture supernatants, have been used for this purpose. 41, 75, 76 However, these approaches are limited in terms of their capacity to handle large volumes, thus making this procedure extremely tedious. Low-speed overnight centrifugation has been used to process volumes in excess of one liter. 77 However, this low-speed approach is time consuming. Thus, there is an emerging need for quick, reproducible and less laborious procedures that rapidly reduce the volume of the cell culture supernatant to be processed.
Pham et al. 78 and Zhang et al. 79 have both described a precipitation method to concentrate lentiviral vectors involving the coprecipitation of viral supernatants with calcium phosphate and poly-L-lysine, respectively. In this way, volumes were markedly decreased, but recovery of infectious virus was rather low (32-50%). One problem the methods outlined above have in common is that cellderived components are concentrated along with the vector particles leading to potential immune and even inflammatory responses. 80 Thus, these approaches generate rather impure virus preparations and additional steps, including chromatography-based approaches are needed to remove contaminating host-cell components from the virus preparation. Recently, methods based on anion exchange chromatography of HIV-1 vectors pseudotyped with VSV.G and baculovirus glycoprotein 64 have been successfully established. [81] [82] [83] Titer determination. To standardize the number of viral particles administered to patients, it is crucial to accurately titrate the virus for each individual vector production. However, titering procedures of lentiviral vectors are still plagued by large intra-and inter-assay variation. Furthermore, a whole range of different methods is used by individual laboratories. Some of these methods are based on the number of vector particles present in a virus stock, whereas others are derived from the number of provirus copies in transduced target cells. Virus particle numbers can be determined using real-time polymerase chain reaction (PCR) based on strong-stop cDNA present in virions 84 or Lentiviral vectors in cancer immunotherapy K Breckpot et al using DNA extracted from transduced cells. 85, 86 Alternatively, the amount of virus proteins present in virus cores such as p24 gag are determined by enzyme-linked immunosorbent assay to arrive at relative particle titers. 87 Titration assays based on vector-encoded reporter gene expression using fluorescence-activated cell sorting analysis of cells transduced with varying amounts of the virus have been widely used. 88 An important factor is the cell line used for titration, as receptors for a given glycoprotein may vary from cell line to cell line. Frequently, a cell line (such as HeLa or 293 cells) is chosen because it is considered generally permissive to infection rather than representing the natural tropism of the virus from which the glycoprotein was derived.
Taken together, as each method produces different results, one should pay attention to the quantification method used before comparing results.
Lentiviral transduction of DCs
Efficient transduction of human DC with transgenic vectors has been challenging for several reasons. Human DCs are usually generated from peripheral blood-derived quiescent CD14
+ progenitors or from mitotically hypoactive primitive CD34 + -derived progenitors cells (hematopoietic stem cells). Therefore, the capacity of lentiviral vectors to transduce quiescent and nondividing cells turned out to be an important asset for DC transduction. The first successful transduction of human monocytederived DC (MoDC) with lentiviral vectors was described by Unutmaz et al. 89 94 However, for murine BMDC, the kinetics are somewhat more complicated. When tNGFR is used as a reporter gene, around 83% of cells are tNGFR positive on day 2 after transduction. Six days after transduction, this percentage decreases to on average 30%. However, with eGFP as a reporter gene, the opposite is observed. The expression of eGFP gradually increases from around 47% on day 2 to 65% on day 6. Using eGFP-encoding lentiviral particles produced in cells that were simultaneously transfected with a nonviral eukaryotic expression vector carrying tNGFR and vice versa, our group demonstrated that nonviral tNGFR is delivered by eGFP-encoding lentiviruses on day 1 after transduction (37% tNGFR positive). The tNGFR positivity decreases with time and almost disappears by day 3 after transduction. This process has been described as pseudotransduction. 100 No pseudotransduction with nonviral eGFP delivered by tNGFRencoding lentiviruses was observed. 101 Importantly, the variability in transduction efficiency among different reports reflects the diversity in DC sources, techniques and vectors used for transduction.
Besides efficient expression of a transgenic protein in lentivirally transduced DC, it is of paramount importance that transgene-derived peptides are efficiently processed and presented on the DC surface to prime efficiently and activate antigen-specific T cells. The first experiments to test the antigen-presenting capacity of lentivirally transduced DC were performed with established T-cell lines. More importantly, several groups reported in vitro priming of naive T cells against TAA using lentivirally transduced human DC. Thus, Firat et al. 92 showed priming of CD8 + T cells in bulk following in vitro stimulation with melanoma poly-epitope-transduced MoDC. They observed amplification of tetramer-positive CD8 + T cells, which could specifically lyze gp100 and MART-1 peptide-pulsed targets. Our group showed priming of both CD8 + and CD4 + T cells against the poorly immunogenic melanoma antigen MAGE-A3 after in vitro stimulations with DC transduced with a lentivirus encoding the fusion protein Ii80/MAGE-A3. 102 Subcloning of one of the CD8 + T-cell clones enabled the identification of a novel HLA-Cw7-restricted peptide.
A number of groups evaluated the use of lentivirally transduced DC in mouse models as an immunotherapeutic agent against cancer in vivo. The immune response that was induced was characterized and tested for protection against tumor growth. Our group showed that immunization with BMDC lentivirally transduced with OVA induced a strong CTL response, resulting in specific lysis of OVA-expressing tumor cells after in vitro restimulation. Mice immunized with OVA-transduced DC were also capable of specifically eliminating autologous OVA peptide-pulsed spleen cells in vivo. 104 Importantly, the resulting CTL response was protective against a subsequent challenge with a lethal dose of OVA-expressing B16 melanoma cells and slowed down the outgrowth of pre-existing tumors. 103, 104 As these studies used exogenous and strong immunogenic antigens, they may overestimate the effects of lentivirally transduced DC against endogenous TAA.
Nevertheless, Metharom et al. 97 also observed strong protective immunity against subsequent challenge with B16 melanoma after immunization with BMDC transduced with the endogenously expressed TAA, TRP-2. Immunization with TRP-2-transduced BMDC also improved survival of mice with pre-existing tumors.
Taken together, these studies show that lentivirally transduced DC can present tumor antigen-derived peptides, and that in mouse models, the immune response mounted by lentivirally transduced DC is protective against subsequent tumor challenge and induces regression of pre-established tumors. This suggests that lentivirally transduced DC might be effective in therapeutic treatment of melanoma and other tumors.
Direct administration of lentiviral vectors
Immune responses and inhibition of tumor growth after direct administration of tumor antigen-encoding lentiviral vectors
On the basis of the successes of virally mediated genetherapy approaches, where viral vectors are used to Lentiviral vectors in cancer immunotherapy K Breckpot et al deliver a corrected version of a gene to the appropriate cells, the use of TAA-encoding lentiviral vectors has been explored for generating antitumor responses in vivo. The premise of this approach is that lentiviral vectors when administered directly in vivo are able to specifically transduce APC and in particular DC. These DC will then mature, present antigen and migrate to the lymph node where they can effectively prime T cells that will in turn migrate to the tumor site. Several groups have presented evidence for this selective in vivo transduction of DC. VandenDriessche et al. 77 were the first to show that APC within the spleen cells are selectively transduced on in vivo administration of lentiviral vectors. Palmowski et al. 105 also showed that a small percentage of GFP positive CD11c + cells (0.3 to 0.4%) were recovered from the spleen after in vivo administration of lentivirus. When we tried to analyze the cells that were transduced within the draining lymph node on lentiviral administration we only found a very small percentage (o0.1%) of GFPpositive cells. 104 When dissecting the cell populations that were transduced by analyzing frozen draining lymph node sections by immunofluorescence, Esslinger et al. 98 found that the majority of the transduced cells were CD11c + DC. Nevertheless, about 10% of the cells that were transduced could not be identified with the markers used in this analysis. Recently, He et al. 106 demonstrated that DC residing in the skin and not lymph node resident DC are predominantly transduced upon footpad injection of eGFP-encoding lentivirus. Furthermore, they showed that the lentivirally infected skin DC are responsible for priming of T cells in the lymph nodes. The ultimate measure for the value of direct administration of lentivirus in tumor immunology is the degree of antigen-specific CTL induction. Using HLA-Cw3 as a model antigen, antigen-specific CTL responses could be generated on direct administration of lentiviral vectors. 98 When comparing immune responses generated by direct administration of lentivirus with vaccination with DC that were transduced with lentivirus ex vivo, superior immune responses were generated by direct administration of lentivirus both in terms of strength and longevity. Similar results were obtained in HLA-A*0201 transgenic mice using a lentivirus encoding a minigene containing the dominant MART-1/Melan-A HLA-A*0201 epitope. Using OVA as a model antigen, we confirmed that direct administration of lentiviral vectors is superior to vaccination with ex vivo-transduced DC, both in terms of the number of interferon (IFN)-g producing CTL as determined by ELISPOT in vitro and the lytic capacity of CTL determined by an in vivo CTL assay. Moreover, memory CTL responses were significantly stronger with direct lentivirus administration. Other studies have also shown potent immune responses on direct in vivo administration of lentiviral vectors encoding relevant tumor antigens such as NY-ESO 105 or TRP-2, 107 although no direct comparison with ex vivo-transduced DC was performed here. Recently, Chapatte et al. 108 compared direct administration of a full length human MART-1/Melan-Aencoding lentiviral vector with MART-1 peptide-adjuvant immunization in a HLA-A*0201 transgenic mouse model and found that the anti-MART-1 immune response was higher for the lentivirus injection than for the peptide-adjuvant vaccination. 108 Although the generation of a specific CTL response is a convenient read-out for the success of a vaccination strategy, there are many examples of discrepancies between immune responses and antitumor responses. 109 Therefore it is crucial not only to evaluate the TAAspecific immune response but also the influence of the treatment on tumor growth. Whereas Rowe et al. 110 showed significantly improved protection of direct administration of an OVA-encoding lentiviral vector against a subsequent tumor challenge, no data was shown about the therapeutic efficacy of this treatment. Using a similar OVA-encoding lentiviral vector we could show that direct administration of lentiviral vectors offers increased protection to a subsequent tumor challenge compared to DC vaccination and a significantly improved survival of tumor bearing mice. This increased survival was only marginally dependent on the amount of transducing units that were administered to the animals as 2 Â 10 6 and 10 7 TU resulted in similar survival curves. In contrast, increased numbers of DC (5 Â 10 5 vs 10 5 ) yielded a significantly better survival. 104 In another study using TRP-2 as a tumor antigen, improved survival of mice receiving lentivirus-encoding TRP-2 was reported compared to irrelevant lentivirus. 107 Taken together, there is substantial evidence for the induction of specific CTL responses by TAA-encoding lentiviral vector administration in vivo. There are also important indications that this treatment can induce protective immunity and our work also shows that direct lentivirus administration results in increased survival, not only compared to controls but also compared to vaccination with ex vivo-transduced DC.
Immunogenicity of lentiviral vectors
Although the currently used lentiviral vectors are -when compared to other viral systems -almost devoid of viral proteins, as described in the previous section, administration of lentiviral vectors does not provoke immunological tolerance, but instead elicits powerful CTL responses against transgene-encoded proteins. This suggests a certain degree of immunogenicity of lentiviral vectors or components present in virus preparations, leading to activation of innate viral-sensing pathways and ultimately resulting in a strong adaptive immune response. It was already shown in 1997 that wild-type HIV-1, from which most recombinant lentiviruses are derived, induces cell-and antibody-mediated responses in humans. [111] [112] [113] Moreover, recently it has been demonstrated in vitro that wild-type HIV-1 activates a subset of DC, the plasmacytoid DC (pDC), through engagement of TLR 7, a pattern recognition receptor (PRR) for ssRNA. 114, 115 On infection, these pDC produce high levels of type I IFN, which are potent antiviral cytokines that induce the maturation of pDC as well as the maturation of other DC subsets. 114, 116 This DC maturation, in turn, can lead to activation of the adaptive immune system. As the recombinant lentiviral vectors are HIV-derived and contain ssRNA by necessity, they may also trigger a similar innate immune response.
The direct influence of lentiviral vectors on MoDC, which is the DC subset that has been most extensively used for both in vitro experiments and DC vaccination of cancer patients, has been previously studied, but remains controversial. Gruber et al. 31 reported that transduction of immature MoDC with lentiviruses at multiplicity of injection (MOI) 5 does not result in phenotypical or Lentiviral vectors in cancer immunotherapy K Breckpot et al functional maturation, whereas Tan et al. 117 described that transduction of immature MoDC with a MOI of 500 results in upregulation of adhesion, costimulatory and HLA molecules. Furthermore, Tan et al. showed that these DC display enhanced allo-stimulatory capacities and display an altered cytokine secretion pattern. Our data indicate that transduction of DC at low MOI (1.5) results in considerable transgene delivery (32712%, n ¼ 3), but does not lead to activation, whereas transduction at higher MOI leads to phenotypical and functional maturation, confirming the results of Tan et al. (Breckpot et al., unpublished data) . To elucidate the mechanisms mediating this lentivirus-induced activation, Tan et al. investigated the role of protein kinase R (PKR), and demonstrated that this cytosolic receptor, which interacts with dsRNA, an intermediate in the lentiviral replication, is phosporylated on transduction at high MOI. This was confirmed by our group (unpublished data). The phosphorylation of PKR leads to the phosphorylation of IkB and subsequent activation of the nuclear factor kB, and thus, the transcription of several genes with antiviral activity, 118, 119 such as IFN-a secreted by MoDC on lentiviral transduction, 31 Breckpot et al., unpublished data).
Toll-like receptors are another important PRR for sensing viral infections. 120 Therefore, we evaluated the activation of TLR 2, 3 and 8 -all expressed both on blood-derived myeloid DC and in vitro-generated IL-4/ GM-CSF MoDC -by VSV.G pseudotyped, secondgeneration lentiviral vectors. In a reporter system using 293T cells transfected with each of these TLR together with a luciferase construct driven by the NF-kB promoter, we demonstrated that transduction at a MOI of 15 or higher resulted in activation of TLR 2, 3 and 8, which are probably engaged by virion components, dsRNA (a viral replication intermediate) and ssRNA (the viral genome), respectively. We further showed that this activation is TLR dependent, as lentiviral transduction of 293T cells transfected with only the luciferase construct did not result in enhanced luciferase activity. Furthermore, we demonstrated that the observed effects were an outcome of the transduction of the 293T cells, as heatinactivation of the viruses or pre-treatment of the viruses with a blocking anti-VSV.G antibody resulted in decreased luciferase activity. Although the downregulation of luciferase activity was less than for TLR 3 and TLR 8, the downregulation observed for TLR2 was unexpected, as TLR 2 -in contrast to TLR 3 and TLR 8 -is localized on the DC surface and has been documented to interact with virions. 121 Assesment of the role of VSV.G on the activation of TLR 2 demonstrated that VSV.G is partially responsible for the observed TLR 2 activation.
The in vitro studies described above show that MoDC are activated by VSV.G-pseudotyped lentiviral vectors. However, the activation of conventional DC in vivo hasto our knowledge -not been studied. In contrast, a role for pDC on in vivo administration of lentiviral vectors has been suggested by Brown et al. 122 They show that administration of lentiviral vectors to mice triggers a rapid and transient type I IFN response. The observed effect was independent of the envelope pseudotype, but dependent on functional vector particles, suggesting the necessity of cell entry. In vitro challenge of APC suggested that pDC are responsible for this response. Although the precise mechanism of pDC activation is not investigated, the authors suggest a role for TLR 7 based on its endosomal localization and its interaction with ssRNA. Furthermore, as reverse transcription of the viral genome occurs in the viral particle itself, 123 they do not exclude the possibility that alternate DNA PRR 124, 125 or TLR 9 is triggered by the lentiviral vectors. They further suggest the presence of additional elements within the vector and/or target cells that are involved in triggering the innate host response, as TLR 7/9 antagonists are not sufficient to prevent the administered lentiviruses to induce a type I IFN response (unpublished data by Brown BD and Sitia G).
A recent report by Pichlmair et al. 126 reported on the presence of tubulovesicular structures (TVS) of cellular origin, carrying nucleic acids, including DNA plasmids originally used for lentivirus production within VSV.Gpseudotyped lentivirus preparations. These TVS act as a stimulus for innate antiviral responses, triggering TLR 9 and inducing type I IFN production by pDC. They further demonstrate that removal of these TVS markedly reduces the capacity of the lentiviral vectors to activate pDC and that these TVS alone are sufficient to stimulate pDC and act as a potent adjuvant in vivo, eliciting both T-and B-cell responses to coadministered proteins. Their results highlight the important role of by-products of virus production in determining the immunostimulatory properties of recombinant virus preparations.
In the Introduction, it is mentioned that more and more data indicate that the establishment of a strong antitumor response is dependent on an inflammatory environment (signal 3) alongside functional recognition of T cells by APC, and that this can be achieved by strong activation of the innate arm of the immune system, in particular through TLR. Two studies, one by Yang et al. and the other by Lang et al., clearly demonstrated that tolerance of antigen-specific CTL could be broken by persistent TLR ligation. 6, 7 Furthermore, it has been recently described that signaling through certain combinations of TLR on DC not only provided a synergy with respect to the production of cytokines such as IL-12, which is essential for skewing CD4 + T cells toward a Th1 phenotype, 12, 13 but also offered protection from inhibitory CD4 + T cells that quench the antitumor immune response.
14 In addition to breaking tolerance, a productive CD4 + T-cell response is required for the induction of a powerful CTL response. Although earlier work shows that CTL responses can be induced in the absence of CD4 + T-cell help, 127 several recent studies prove that CD4 + T-cell help is indispensable for generation of effective memory CTL and recall responses, even in the case of viruses that elicit potent primary CTL responses. [128] [129] [130] For direct administration of lentiviral vectors, several groups have shown that both a CTL response and an antigen-specific CD4 + T-cell response can be induced. 98, 104, 110 However, not much data is available on the role of CD4 + T-cell help in CTL induction. Esslinger et al. showed that CD4 depletion reduces primary CTL response on direct administration of lentivirus. We showed that although their was a larger requirement for CD4 + T-cell help during the primary response in case of immunization with DC transduced ex vivo compared to direct administration of lentiviral vectors, CD4 + T-cell depletion strongly reduced the capacity to mount a recall CTL response in both cases. 104 Interestingly, Marzo et al. 131 showed that in the case of a Lentiviral vectors in cancer immunotherapy K Breckpot et al VSV infection, a functional CD8 + T-cell memory response can be generated in the absence of CD4 + T cells, this in contrast to an infection with Listeria monocytogenes. These authors suggest that the difference might be due to the fact that VSV can directly infect DC whereas LM needs to be cross-presented. As the lentiviral vectors that have been used so far for direct in vivo adminisitration all have been pseudotyped with a VSV.G envelope, it needs to be further examined to what extent the CTL response is CD4 + T-cell dependent. Overall, it has become clear from the above-discussed studies on activation of MoDC and pDC by lentiviral vectors, that lentiviral vectors as they are currently produced and processed induce DC activation through TLR signaling and other mechanisms, explaining their potency as antitumor vaccine.
Toward specific targeting of DCs by in vivo lentiviral vector administration?
Although recent data show that there is specificity for DC transduction in vivo when administering lentiviral vectors, this issue along with the question, which other cell types are further transduced, still needs to be explored in more detail. One of the most important questions that remain is whether it is sufficient to transduce only DC, and if yes, which subtype of DC yields better immune responses. Several approaches can be taken to analyze this more clearly. One way would be to replace the constitutively active promoters, such as CMV, CMV enhancer/chicken b-actin core promoter (CAG) and so on by DC-specific promoters. Thus, the CD11c promoter could be used to limit expression in myeloid DC, 132 whereas the BDCA-2 and langerin promoter should result in exclusive expression in pDC 133 and Langerhans cells, 134 respectively. As the expression level of the transgene could be significantly reduced compared to constitutively active promoters, the question remains whether this will be a valuable approach. Another approach that has been attempted is to modify the viral envelope in such a way that the infectivity of the virus is restricted to or preferential for a certain cell type. Modifications can be made chemically, but recently a convenient system was described for retroviral vectors where the viral-packaging mechanism is exploited to modify the viral envelope. As the virus is generated in a producer cell line, on budding it incorporates part of the cell membrane in its envelope. If a specific receptor is overexpressed on the cell membrane of a producer cell line, then this will also be displayed on the viral envelope. When overexpressing stem cell factor (SCF) on the cell membrane of an ecotropic producer cell line, Chandrashekran et al. 135, 136 showed that retrovirus thus produced was able to preferentially transduce c-kit expressing human stem cells. Recently, Yang et al. 137 demonstrated that this approach can also be applied for lentiviruses. This method could thus be modified to generate lentiviral vectors that can specifically target DC (or other cell types) and still yield high expression of the transgene. Receptors that could be used include CD40 ligand, which interacts with CD40, and CTLA-4, which interacts with CD80 and CD86. As many of these receptors are expressed on other cell types than DC, specificity will still be limited. Specific targeting of DC has been achieved by using antibodies directed against C-type lectins, such as DEC-205 138, 139 and DC-SIGN, 133 which efficiently endocytose their cargo on binding. As molecular cloning of classic antibodies or fragments thereof offers serious challenges, alternatives have been explored. In members of the family of camilidae (i.e., Dromedary, Camel and Llama) a unique class of antibodies was described, which are only composed of two identical heavy chains as opposed to the conventional (four-chain) antibody repertoire. 140 Thus, their antigen-binding part is composed of only one single immunoglobulin variable region (termed VHH, or Nanobody). These antigen-specific antibody fragments offer many advantages. They display a high solubility and the capacity to refold after denaturation although retaining their binding capacity. Cloning and selection of antigen-specific nanobodies obviate the need for construction and screening of large libraries, and for lengthy and unpredictable in vitro affinity maturation steps. Moreover, as nanobodies can be fused to other proteins, it should be possible to present them on the cell membrane of a producer cell line, such as HEK 293T, thus, generating lentiviral particles that incorporated a DC-specific nanobody in their envelope during budding as described above. This approach would combine the specificity of antibody targeting with the advantages of lentiviral vectors.
All things considered, it remains to be seen whether specific targeting toward DC will be beneficial for lentivirus-based cancer immunotherapy, but the recent report by He et al. 106 provides an important first clue for the feasibility of such an approach, as transduction of a specific subset of dermal DC seems to be responsible for the immune response.
Nevertheless, as recent data showed that a viral infection promotes cross priming to DC, transduction of cells other than DC near the injection site might further improve subsequent processing and presentation of antigen by the DC. 141 These issues need to be clarified in future by side-by-side comparisons of immunizations with broadly directed lentiviral vectors and vectors modified for specific transduction of DC.
Lentiviral vectors as a therapeutic tool: translation of preclinical animal models to the clinic
Translating lentivirus-based animal cancer immunotherapy models to the clinic is challenging and requires a thorough evaluation of several issues: (1) dose toxicity studies, (2) biodistribution analyses and (3) testing of immunogenicity including therapeutic experiments. Furthermore, with regard to safety issues, it is critical to evaluate the occurrence of RCL and to strive for selective transduction of DC as discussed above.
The main focus of the preclinical animal studies described in an earlier section of this paper was evaluating the immune response generated against the delivered transgene and testing the possibility of using TAA-encoding lentiviral vectors as a prophylactic and/ or therapeutic tool. In these studies, the potency of lentiviral vectors as anticancer vaccine has been repeatedly demonstrated.
To get additional relevant information for human trials, an important issue that needs to be addressed in future animal studies is the in vivo biodistribution and Lentiviral vectors in cancer immunotherapy K Breckpot et al replication of administered lentiviral vectors. Regarding biodistribution, several new tools for in vivo imaging in small animals have been described. For instance, lentiviruses encoding the sodium iodide importer or luciferase could be used for noninvasive gamma camera imaging and bioluminisence imaging, respectively. These tools will allow the evaluation of the optimal route of administration -footpad, intravenous, intradermal, subcutaneous or intramuscular injection -as well as the minimal dose required to transduce APC in situ, always aiming for an optimal antigen-specific immune response. To date, only a few publications have addressed biodistribution of lentiviral vectors on in vivo administration. The results of these studies suggest that depending on the route of administration, different DC subsets are selectively transduced in vivo. For instance, Esslinger et al. 98 first evaluated tissue distribution after administration of a lentivector vaccine into the footpad of mice by a sensitive PCR assay, demonstrating transgene positivity at the injection site in lymph nodes and spleen. They further performed immunohistochemical analysis of the draining lymph nodes and spleen, demonstrating that the transgene positive cells are mainly DC. This was later extended by He et al., 106 who demonstrated that skin-derived DC (CD8
are efficiently transduced on a single cutaneous injection of lentiviral vectors and that these DC subsequently migrate to the draining lymph nodes where they induce potent CTL responses.
Another important issue that needs to be clarified before lentiviral vectors can be used as a clinical tool is dose toxicity. Here, the minimal dose required to transduce APC and still induce an effective antitumor immune response without significant side effects needs to be carefully determined.
Concerns in view of lentiviral vectors as anticancer vaccine
Gene transfer vectors based on lentiviruses provide effective means for the delivery, integration and expression of transgenes in both dividing and nondividing mammalian cells. As mentioned earlier in this paper, many efforts have been undertaken to optimize the lentiviral vector system and this at the level of biosafety, good manufacturing practise (GMP) production, efficiency of gene transfer and gene expression. These efforts have led to the GMP production of lentiviral vectors devoid of RCL and producer cell contaminants, and to approval for use of lentiviral vectors in clinical applications.
However, some concerns about biosafety of lentiviral vectors, mainly the generation of RCL and insertional mutagenesis remain. The risk of the generation of RCL through uncontrolled recombination in vector productions was largely addressed by engineering split plasmid systems for the generation of lentiviral particles, whereby a minimal overlap between the plasmids minimizes the risk of homologous recombination. So far, no RCL have been detected in virus preparations using highly sensitive techniques. 142, 143 In vivo, however, the integrated provirus could be rescued by recombination with wild-type retrovirus present in the patient (either HIV or some other virus that shares sequence homology to the provirus). The possibility that retroviral function could be provided in trans or that the vector genome could recombine with human endogenous retroviral sequences is an issue that will be difficult to assess in animal studies. Another risk related to such recombinations is the dissemination of new hybrid viruses from patients undergoing genetherapy treatment. Long-term monitoring of patients will be the most robust method for the detection of adverse events associated with lentivirus integration.
With the recent reports of leukemia occurring in three out of ten SCID patients after treatment with CD34 + stem cells retrovirally transduced with the Y c gene, 144 the risk of insertional mutagenesis with integrating vectors, including lentiviruses, is currently a major concern. Nevertheless, the comprehensive study by Dave et al. 145 of 3000 insertions from nearly 1000 retrovirally induced murine hematopoietic tumors indicates that this particular case might be the result of an unfortunate conjunction of events, where the vector encoded Y c gene and the insertion site, the Lmo2 gene are collaborating oncogenes. Therefore, this turn of events should be highly exceptional as most therapeutic genes will not have oncogenic potential. It remains to be seen if lentiviral vectors will be safer than retroviral vectors, but continued efforts are being made to increase the safety of these vectors as well. 146, 147 A potential concern is that HIV-1 favors active genes for integration. 148 Wildtype HIV, however, is not recognized to cause oncogenesis as superinfection with other viruses and loss of immune surveillance, not HIV itself, are responsible for malignancies observed in AIDS. Nevertheless, it has been described that delivery of nonprimate lentiviral vectors to fetal and neonatal mice leads to a high incidence of lentiviral vector-associated tumorigenesis. 146 Therefore, efforts toward targeted integration in noncoding sequences as well as the development of nonintegrating lentiviral vectors are ongoing. 149, 150 With regard to targeted integration, the use of zinc fingers 151 and the phage integrase phiC31 152, 153 have been described to mediate efficient, site-specific integration of target genes resulting in functional protein expression. To render the lentiviral vectors integration defective, mutations have been included in the integrase coding sequence. 154 Recent, in vitro studies demonstrated that these integration-defective vectors mediate stable transduction. 155, 156 Furthermore, it has been shown in vivo in rodent ocular tissue that efficient and sustained transgene expression is obtained, resulting in substantial rescue of clinically relevant models of retinal degeneration, thus, demonstrating the potential of nonintegrating lentiviral vectors for therapeutic applications. 149 However, all things considered, the use of lentiviral vectors for cancer immunotherapy holds less risk for oncogenesis. First, the level of transgene expression (and consequently the number of integrations) required to elicit an immune response is much lower than for obtaining therapeutic expression levels of a missing protein. As shown in Table 2 the doses used for immunization of mice with lentiviral vectors range from 1 Â 10 6 to 2 Â 10 7 TU, whereas the doses used for gene therapy range from 10 7 to 6 Â 10 8 TU, which is about tenfold higher. Moreover, it has to be mentioned that for immunotherapy, the lentiviral vectors are systemically administered, whereas in the case of gene therapy, the lentiviral vectors are most often administered in the Lentiviral vectors in cancer immunotherapy K Breckpot et al tissue of interest, resulting in transduction of these tissue-specific cells. [157] [158] [159] [160] [161] Second, when using ex vivo-transduced DC or targeting DC in vivo, terminally differentiated, nondividing cells are transduced as opposed to extensively proliferating cells in the SCID trial, thereby posing less of a risk for oncogenic transformations. Finally, when an immune response is induced in vivo, the effector cells will most likely kill cells that express the target antigen, including the transduced APC, thus, further reducing the risk for oncogenesis. Even so, efforts to further improve the biosafety of lentiviral vectors should be continued.
Future perspectives
Viral vectors based on retro-and lentiviral genomes will continue to play an important role as gene transfer reagents, because of their numerous advantages, among which (1) long-term expression, (2) low toxicity, (3) high capacity and (4) low anti-vector immunity allowing repeated administration. Besides expression of antigens for immunotherapeutic purposes, lentiviruses have other potential applications. They are very useful tools in the search for the function of newly identified molecules. Thus, the function of DC-related molecules that are picked up in microarrays can be investigated easily through either lentivirus-mediated overexpression or RNA interference through short hairpin RNA. 162 Another application is the simultaneous modification of DC with antigen and immunomodulatory molecules via bicistronic vectors to influence the outcome of the immune response. Cotransduction with antigen and a costimulatory molecule could result in superactivated DC that are better stimulators than DC expressing the antigen alone. Lentiviral transduction of DC with CD40 ligand 163 and gp34/OX40 ligand 164 has already been shown to induce autonomous maturation and increased allostimulatory capacity, respectively. Similarly, cotransduction with antigen and a tolerogenic molecule, such as IL-10 or B7-H1, could result in antigen-specific tolerance, required in autoimmune diseases.
Furthermore, the fact that direct injection of lentivirus reliably induces strong CTL responses against the transgene opens the possibility to exploit this technology for research applications other than those related to immunotherapy. Examples include the use of lentiviral vectors in combination with HLA transgenic mice as an efficient method for the identification of new epitopes that are also presented by human cells in vitro 165 or for other applications where in vitro human systems are inefficient or incomplete, such as the evaluation of the immune response in the presence or absence of certain components of the immune system, such as NK cells or Treg. 
